|
|
LC401 | PD-L1检测的非小细胞肺癌组织芯片,附病理分级、TNM、临床分期和免疫组化(PD-L1(Sp263))结果,40例/40点 | 点 数 | 40 | 例 数 | 40 | 行 数 | 5 | 列 数 | 8 | 点直径(mm) | 1.5 | 厚度(µm) | 5.0 | 组织阵列类型 | 石蜡包埋 | 种 属 | 人类 | QA/QC | | Applications | Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page. | Notes | 1.Please keep the slides at 4 ℃ after receiving, and make experiment within 3 months will be better. 2.Bake the slides for 30 minutes at 60℃ before the experiment; 3.Please choose a gentle repair method to avoid tissue detachment. |
|
|
|
Legend:
|
|
Malignant (I) Malignant (IB) Malignant (IIA) Malignant (IIIA) Malignant (IIIB)
|
|
|
|
Pos | No | Age | Sex | Organ_Anatomic_Site | Pathology_diagnosis | Grade | TNM | Stage | Type | PD-L1 |
A1 | 1 | 56 | M | Lung | Squamous cell carcinoma | 2 | T2N3M0 | IIIB | Malignant | TC≥25% |
A2 | 2 | 70 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | TC≥25% |
A3 | 3 | 61 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | TC=100% |
A4 | 4 | 63 | M | Lung | Squamous cell carcinoma | 2 | T3N1M0 | IIIA | Malignant | TC≥85% |
A5 | 5 | 64 | M | Lung | Squamous cell carcinoma | 2 | T2N1M0 | IIA | Malignant | TC≥25% |
A6 | 6 | 58 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | TC≥25% |
A7 | 7 | 65 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | TC=100% |
A8 | 8 | 50 | M | Lung | Squamous cell carcinoma | 3 | T2N0M0 | IB | Malignant | TC≥25% |
B1 | 9 | 56 | M | Lung | Squamous cell carcinoma | 3 | T2N0M0 | IB | Malignant | TC=30% |
B2 | 10 | 60 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | TC=25% |
B3 | 11 | 54 | M | Lung | Squamous cell carcinoma | 2 | T2N2M0 | IIIA | Malignant | TC=30% |
B4 | 12 | 69 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | TC=80% |
B5 | 13 | 57 | M | Lung | Squamous cell carcinoma | 3 | T2N0M0 | IB | Malignant | TC≥25% |
B6 | 14 | 58 | M | Lung | Adenosquamous carcinoma | 3 | T2N0M0 | IB | Malignant | TC=25% |
B7 | 15 | 46 | M | Lung | Adenosquamous carcinoma | 3 | T2N0M0 | IB | Malignant | TC=100% |
B8 | 16 | 52 | M | Lung | Adenocarcinoma | 2--3 | T2N2M0 | IIIA | Malignant | TC≥25% |
C1 | 17 | 62 | M | Lung | Adenocarcinoma | 2 | T1N0M0 | I | Malignant | TC≥25% |
C2 | 18 | 70 | M | Lung | Adenocarcinoma | 3 | T2N0M0 | IB | Malignant | TC=85% |
C3 | 19 | 50 | M | Lung | Adenocarcinoma | 3 | T2N0M0 | IB | Malignant | TC≥25% |
C4 | 20 | 40 | M | Lung | Adenocarcinoma | 3 | T2N0M0 | IB | Malignant | TC≥25% |
C5 | 21 | 65 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
C6 | 22 | 35 | F | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
C7 | 23 | 63 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
C8 | 24 | 52 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
D1 | 25 | 65 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
D2 | 26 | 69 | M | Lung | Squamous cell carcinoma | 2 | T3N1M0 | IIIA | Malignant | - |
D3 | 27 | 54 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
D4 | 28 | 54 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
D5 | 29 | 36 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
D6 | 30 | 48 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
D7 | 31 | 27 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
D8 | 32 | 64 | M | Lung | Squamous cell carcinoma | 2 | T2N2M0 | IIIA | Malignant | - |
E1 | 33 | 64 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
E2 | 34 | 46 | F | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
E3 | 35 | 58 | M | Lung | Squamous cell carcinoma | 2--3 | T2N0M0 | IB | Malignant | - |
E4 | 36 | 62 | M | Lung | Squamous cell carcinoma | 3 | T3N1M0 | IIIA | Malignant | - |
E5 | 37 | 57 | M | Lung | Squamous cell carcinoma | 3 | T2N0M0 | IB | Malignant | - |
E6 | 38 | 58 | M | Lung | Squamous cell carcinoma | 3 | T2N0M0 | IB | Malignant | - |
E7 | 39 | 58 | M | Lung | Squamous cell carcinoma | 3 | T3N2M0 | IIIA | Malignant | - |
E8 | 40 | 48 | M | Lung | Squamous cell carcinoma | 3 | T2N0M0 | IB | Malignant | - | Tissue Marker |
|
|